The autoimmune concept of multiple sclerosis

Presse Medicale

Volumn 44, Issue 4, 2015, Pages e103-e112

  Nicol, Bryan ^a   Salou, Marion ^a   Laplaud, David Axel ^a   Wekerle, Hartmut ^b  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; NATALIZUMAB; OCRELIZUMAB; RITUXIMAB; TERIFLUNOMIDE;

ADAPTIVE IMMUNITY; ASTROCYTE; AUTOIMMUNITY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG EFFICACY; DRUG TARGETING; GENETIC RISK; GENOME-WIDE ASSOCIATION STUDY; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INFLAMMATORY INFILTRATE; INNATE IMMUNITY; MACROPHAGE; MAST CELL; MICROGLIA; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; REGULATORY T LYMPHOCYTE; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM; TH1 CELL; TH17 CELL; TH2 CELL; TH22 CELL; TH9 CELL; ANIMAL; DISEASE MODEL; IMMUNOLOGY; PATHOLOGY;

ADAPTIVE IMMUNITY; ANIMALS; AUTOIMMUNITY; DISEASE MODELS, ANIMAL; HUMANS; MULTIPLE SCLEROSIS;

EID: 85028202614     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2015.02.009     Document Type: Short Survey

References (122)

1. Compston, A., Coles, A., Multiple sclerosis. Lancet 372 (2008), 1502–1517.
2. Jersild, C., Dupont, B., Fog, T., Hansen, G.S., Nielsen, L.S., Thomsen, M., et al. Histocompatibility-linked immune-response determinants in multiple sclerosis. Transplant Proc 5 (1973), 1791–1796.
3. Sawcer, S., Franklin, R.J.M., Ban, M., Multiple sclerosis genetics. Lancet Neurol 13 (2014), 700–709.
4. Brynedal, B., Duvefelt, K., Jonasdottir, G., Roos, I.M., Akesson, E., Palmgren, J., et al. HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. PLoS ONE, 2, 2007, e664.
5. Wagner, M., Bilinska, M., Pokryszko-Dragan, A., Sobczynski, M., Cyrul, M., Kusnierczyk, P., et al. ALCAM and CD6 - multiple sclerosis risk factors. J Neuroimmunol 276 (2014), 98–103.
6. Lundström, W., Highfill, S., Walsh, S.T.R., Beq, S., Morse, E., Kockum, I., et al. Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity. Proc Natl Acad Sci U S A 110 (2013), E1761–E1770, 10.1073/pnas.1222303110.
7. Gregory, A.P., Dendrou, C.A., Attfield, K.E., Haghikia, A., Xifara, D.K., Butter, F., et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 488 (2012), 508–511.
8. Frohman, E.M., Racke, M.K., Raine, C.S., Multiple sclerosis: the plaque and its pathogenesis. N Engl J Med 354 (2006), 942–955.
9. Lassmann, H., Brück, W., Lucchinetti, C., Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 7 (2001), 115–121.
10. Kidd, D., Barkhof, F., McConnell, R., Algra, P.R., Allen, I.V., Revesz, T., Cortical lesions in multiple sclerosis. Brain 122:Pt 1 (1999), 17–26.
11. Peterson, J.W., Bö L., Mörk, S., Chang, A., Trapp, B.D., Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 50 (2001), 389–400.
12. Lassmann, H., Wekerle, H., Chapter 12 – The pathology of multiple sclerosis. Wekerle ACCLMMNS, (eds.) McAlpine's Multiple Sclerosis, Fourth Edition, 2006, Churchill Livingstone, Edinburgh, 557–599.
13. Junker, A., Ivanidze, J., Malotka, J., Eiglmeier, I., Lassmann, H., Wekerle, H., et al. Multiple sclerosis: T-cell receptor expression in distinct brain regions. Brain 130 (2007), 2789–2799.
14. Skulina, C., Schmidt, S., Dornmair, K., Babbe, H., Roers, A., Rajewsky, K., et al. Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc Natl Acad Sci U S A 101 (2004), 2428–2433.
15. Babbe, H., Roers, A., Waisman, A., Lassmann, H., Goebels, N., Hohlfeld, R., et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 192 (2000), 393–404.
16. Madsen, L.S., Andersson, E.C., Jansson, L., krogsgaard, M., Andersen, C.B., Engberg, J., et al. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat Genet 23 (1999), 343–347.
17. Oksenberg, J.R., Panzara, M.A., Begovich, A.B., Mitchell, D., Erlich, H.A., Murray, R.S., et al. Selection for T-cell receptor V beta-D beta-J beta gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis. Nature 362 (1993), 68–70.
18. Pette, M., Fujita, K., Kitze, B., Whitaker, J.N., Albert, E., Kappos, L., et al. Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology 40 (1990), 1770–1776.
19. Martin, R., Jaraquemada, D., Flerlage, M., Richert, J., Whitaker, J., Long, E.O., et al. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J Immunol 145 (1990), 540–548.
20. Berer, K., Mues, M., Koutrolos, M., Rasbi, Z.A., Boziki, M., Johner, C., et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 479 (2011), 538–541.
21. Prineas, J.W., Wright, R.G., Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab Invest 38 (1978), 409–421.
22. Ajami, B., Bennett, J.L., Krieger, C., McNagny, K.M., Rossi, F.M.V., Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat Neurosci 14 (2011), 1142–1149.
23. Tran, E.H., Hoekstra, K., Van Rooijen, N., Dijkstra, C.D., Owens, T., Immune invasion of the central nervous system parenchyma and experimental allergic encephalomyelitis, but not leukocyte extravasation from blood, are prevented in macrophage-depleted mice. J Immunol 161 (1998), 3767–3775.
24. Lieberman, A.P., Pitha, P.M., Shin, H.S., Shin, M.L., Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc Natl Acad Sci U S A 86 (1989), 6348–6352.
25. Meares, G.P., Ma, X., Qin, H., Benveniste, E.N., Regulation of CCL20 expression in astrocytes by IL-6 and IL-17. Glia 60 (2012), 771–781.
26. Huang, D., Shi, F.-D., Jung, S., Pien, G.C., Wang, J., Salazar-Mather, T.P., et al. The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J 20 (2006), 896–905.
27. Hao, J., Liu, R., Piao, W., Zhou, Q., Vollmer, T.L., Campagnolo, D.I., et al. Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J Exp Med 207 (2010), 1907–1921.
28. Shi, F.-D., Zhou, Q., Natural killer cells as indispensable players and therapeutic targets in autoimmunity. Autoimmunity 44 (2011), 3–10.
29. Sand, K.L., Knudsen, E., Rolin, J., Al-Falahi, Y., Maghazachi, A.A., Modulation of natural killer cell cytotoxicity and cytokine release by the drug glatiramer acetate. Cell Mol Life Sci 66 (2009), 1446–1456.
30. Kastrukoff, L.F., Morgan, N.G., Zecchini, D., White, R., Petkau, A.J., Satoh, J., et al. Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B. Neurology 52 (1999), 351–359.
31. Steinbach, K., Piedavent, M., Bauer, S., Neumann, J.T., Friese, M.A., Neutrophils amplify autoimmune central nervous system infiltrates by maturing local APCs. J Immunol 191 (2013), 4531–4539.
32. Aubé B., Lévesque, S.A., Paré A., Chamma, É., Kébir, H., Gorina, R., et al. Neutrophils mediate blood-spinal cord barrier disruption in demyelinating neuroinflammatory diseases. J Immunol 193 (2014), 2438–2454.
33. Ishizu, T., Osoegawa, M., Mei, F.-J., Kikuchi, H., Tanaka, M., Takakura, Y., et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 128 (2005), 988–1002.
34. Silverman, A.J., Sutherland, A.K., Wilhelm, M., Silver, R., Mast cells migrate from blood to brain. J Neurosci 20 (2000), 401–408.
35. Couturier, N., Zappulla, J.P., Lauwers-Cances, V., Uro-Coste, E., Delisle, M.-B., Clanet, M., et al. Mast cell transcripts are increased within and outside multiple sclerosis lesions. J Neuroimmunol 195 (2008), 176–185.
36. Rozniecki, J.J., Hauser, S.L., Stein, M., Lincoln, R., Theoharides, T.C., Elevated mast cell tryptase in cerebrospinal fluid of multiple sclerosis patients. Ann Neurol 37 (1995), 63–66.
37. Romagnani, S., TH1 and TH2 in human diseases. Clin Immunol Immunopathol 80 (1996), 225–235.
38. Martin, R., McFarland, H.F., McFarlin, D.E., Immunological aspects of demyelinating diseases. Annu Rev Immunol 10 (1992), 153–187.
39. Goverman, J., Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 9 (2009), 393–407.
40. Bettelli, E., Sullivan, B., Szabo, S.J., Sobel, R.A., Glimcher, L.H., Kuchroo, V.K., Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. J Exp Med 200 (2004), 79–87.
41. Cua, D.J., Sherlock, J., Chen, Y., Murphy, C.A., Joyce, B., Seymour, B., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421 (2003), 744–748.
42. Ferber, I.A., Brocke, S., Taylor-Edwards, C., Ridgway, W., Dinisco, C., Steinman, L., et al. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 156 (1996), 5–7.
43. Willenborg, D.O., Fordham, S., Bernard, C.C., Cowden, W.B., Ramshaw, I.A., IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J Immunol 157 (1996), 3223–3227.
44. Panitch, H.S., Hirsch, R.L., Schindler, J., Johnson, K.P., Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 37 (1987), 1097–1102.
45. Dettke, M., Scheidt, P., Prange, H., Kirchner, H., Correlation between interferon production and clinical disease activity in patients with multiple sclerosis. J Clin Immunol 17 (1997), 293–300.
46. Petereit, H.F., Richter, N., Pukrop, R., Bamborschke, S., Interferon gamma production in blood lymphocytes correlates with disability score in multiple sclerosis patients. Mult Scler 6 (2000), 19–23.
47. Drulović J., Mostarica-Stojković M., Lević Z., Stojsavljević N., Pravica, V., Mesaros, S., Interleukin-12 and tumor necrosis factor-alpha levels in cerebrospinal fluid of multiple sclerosis patients. J Neurol Sci 147 (1997), 145–150.
48. Cosmi, L., Maggi, L., Santarlasci, V., Liotta, F., Annunziato, F., T helper cells plasticity in inflammation. Cytometry 85 (2014), 36–42.
49. Roy, A., Liu, X., Pahan, K., Myelin basic protein-primed T cells induce neurotrophins in glial cells via alphavbeta3 [corrected] integrin. J Biol Chem 282 (2007), 32222–32232.
50. Roy, A., Pahan, K., Myelin basic protein-primed T helper 2 cells suppress microglial activation via alphaVbeta3 integrin: implications for multiple sclerosis. J Clin Cell Immunol, 7, 2013, 158.
51. Pedotti, R., De Voss, J.J., Steinman, L., Galli, S.J., Involvement of both “allergic” and “autoimmune” mechanisms in EAE, MS and other autoimmune diseases. Trends Immunol 24 (2003), 479–484.
52. Sabatino, G., Nicoletti, M., Neri, G., Saggini, A., Rosati, M., Conti, F., et al. Impact of IL-9 and IL-33 in mast cells. J Biol Regul Homeost Agents 26 (2012), 577–586.
53. Jäger, A., Dardalhon, V., Sobel, R.A., Bettelli, E., Kuchroo, V.K., Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol 183 (2009), 7169–7177.
54. Zhou, Y., Sonobe, Y., Akahori, T., Jin, S., Kawanokuchi, J., Noda, M., et al. IL-9 promotes Th17 cell migration into the central nervous system via CC chemokine ligand-20 produced by astrocytes. J Immunol 186 (2011), 4415–4421.
55. Langrish, C.L., Chen, Y., Blumenschein, W.M., Mattson, J., Basham, B., Sedgwick, J.D., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201 (2005), 233–240.
56. Stockinger, B., Veldhoen, M., Martin, B., Th17 T cells: Linking innate and adaptive immunity. Semin Immunol 19 (2007), 353–361.
57. Hofstetter, H.H., Toyka, K.V., Tary-Lehmann, M., Lehmann, P.V., Kinetics and organ distribution of IL-17-producing CD4 cells in proteolipid protein 139-151 peptide-induced experimental autoimmune encephalomyelitis of SJL mice. J Immunol 178 (2007), 1372–1378.
58. Ivanov, I.I., McKenzie, B.S., Zhou, L., Tadokoro, C.E., Lepelley, A., Lafaille, J.J., et al. The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126 (2006), 1121–1133.
59. Yang, Y., Winger, R., Lee, P.W., Nuro-Gyina, P.K., Minc, A., Larson, M., et al. Impact of suppressing RORγt in ameliorating central nervous system autoimmunity. Clin Exp Immunol 179 (2015), 108–118.
60. Lock, C., Hermans, G., Pedotti, R., Brendolan, A., Schadt, E., Garren, H., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 8 (2002), 500–508.
61. Brucklacher-Waldert, V., Stuerner, K., Kolster, M., Wolthausen, J., Tolosa, E., Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 132 (2009), 3329–3341.
62. Matusevicius, D., Kivisäkk, P., He, B., Kostulas, N., Ozenci, V., Fredrikson, S., et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 5 (1999), 101–104.
63. Durelli, L., Conti, L., Clerico, M., Boselli, D., Contessa, G., Ripellino, P., et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol 65 (2009), 499–509.
64. Tzartos, J.S., Friese, M.A., Craner, M.J., Palace, J., Newcombe, J., Esiri, M.M., et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 172 (2008), 146–155.
65. Kebir, H., Ifergan, I., Alvarez, J.I., Bernard, M., Poirier, J., Arbour, N., et al. Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann Neurol 66 (2009), 390–402.
66. Hirota, K., Duarte, J.H., Veldhoen, M., Hornsby, E., Li, Y., Cua, D.J., et al. Fate mapping of interleukin 17-producing T cells in inflammatory responses. Nat Immunol 12 (2011), 255–263.
67. Mehling, M., Lindberg, R., Raulf, F., Kuhle, J., Hess, C., Kappos, L., et al. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology 75 (2010), 403–410.
68. Segal, B.M., Constantinescu, C.S., Raychaudhuri, A., Kim, L., Fidelus-Gort, R., Kasper, L.H., et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 7 (2008), 796–804.
69. Hueber, W., Patel, D.D., Dryja, T., Wright, A.M., Koroleva, I., Bruin, G., et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med, 2, 2010, 52ra72.
70. Duhen, T., Geiger, R., Jarrossay, D., Lanzavecchia, A., Sallusto, F., Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 10 (2009), 857–863.
71. Rolla, S., Bardina, V., De Mercanti, S., Quaglino, P., Palma, R.D., Gned, D., et al. Th22 cells are expanded in multiple sclerosis and are resistant to IFN-β. J Leukoc Biol 96 (2014), 1155–1164.
72. Reboldi, A., Coisne, C., Baumjohann, D., Benvenuto, F., Bottinelli, D., Lira, S., et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 10 (2009), 514–523.
73. Río, J., Nos, C., Tintoré M., Téllez, N., Galán, I., Pelayo, R., et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 59 (2006), 344–352.
74. Sospedra, M., Martin, R., Immunology of multiple sclerosis. Annu Rev Immunol 23 (2005), 683–747.
75. Kohm, A.P., Carpentier, P.A., Miller, S.D., Regulation of experimental autoimmune encephalomyelitis (EAE) by CD4+ CD25+ regulatory T cells. Novartis Found Symp 252 (2003), 45–52 [discussion 52–4, 106–14].
76. Reddy, J., Illes, Z., Zhang, X., Encinas, J., Pyrdol, J., Nicholson, L., et al. Myelin proteolipid protein-specific CD4+ CD25+ regulatory cells mediate genetic resistance to experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 101 (2004), 15434–15439.
77. Venken, K., Hellings, N., Hensen, K., Rummens, J.-L., Medaer, R., D'hooghe, M.B., et al. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+ CD25+ regulatory T-cell function and FOXP3 expression. J Neurosci Res 83 (2006), 1432–1446.
78. Putheti, P., Pettersson, A., Soderstrom, M., Link, H., Huang, Y.M., Circulating CD4+ CD25+ T regulatory cells are not altered in multiple sclerosis and unaffected by disease-modulating drugs. J Clin Immunol 24 (2004), 155–161.
79. Feger, U., Luther, C., Poeschel, S., Melms, A., Tolosa, E., Wiendl, H., Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients. Clin Exp Immunol 147 (2007), 412–418.
80. Fritzsching, B., Haas, J., König, F., Kunz, P., Fritzsching, E., Pöschl, J., et al. Intracerebral human regulatory T cells: analysis of CD4+ CD25+ FOXP3+ T cells in brain lesions and cerebrospinal fluid of multiple sclerosis patients. PLoS ONE, 6, 2011, e17988, 10.1371/journal.pone.0017988.
81. Haas, J., Hug, A., Viehöver, A., Fritzsching, B., Falk, C.S., Filser, A., et al. Reduced suppressive effect of CD4+ CD25 high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur J Immunol 35 (2005), 3343–3352.
82. Viglietta, V., Baecher-Allan, C., Weiner, H.L., Hafler, D.A., Loss of functional suppression by CD4+ CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 199 (2004), 971–979.
83. Cerosaletti, K., Schneider, A., Schwedhelm, K., Frank, I., Tatum, M., Wei, S., et al. Multiple autoimmune-associated variants confer decreased IL-2R signaling in CD4+ CD25(hi) T cells of type 1 diabetic and multiple sclerosis patients. PLoS ONE, 8, 2013, e83811, 10.1371/journal.pone.0083811.
84. Michel, L., Berthelot, L., Pettré S., Wiertlewski, S., Lefrère, F., Braudeau, C., et al. Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis. J Clin Invest 118 (2008), 3411–3419.
85. Gourraud, P.-A., Harbo, H.F., Hauser, S.L., Baranzini, S.E., The genetics of multiple sclerosis: an up-to-date review. Immunol Rev 248 (2012), 87–103.
86. Lassmann, H., Experimental models of multiple sclerosis. Rev Neurol (Paris) 163 (2007), 651–655.
87. Sun, D., Whitaker, J.N., Huang, Z., Liu, D., Coleclough, C., Wekerle, H., et al. Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J Immunol 166 (2001), 7579–7587.
88. Trapp, B.D., Bö L., Mörk, S., Chang, A., Pathogenesis of tissue injury in MS lesions. J Neuroimmunol 98 (1999), 49–56.
89. Bitsch, A., Schuchardt, J., Bunkowski, S., Kuhlmann, T., Brück, W., Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 123:Pt 6 (2000), 1174–1183.
90. Höftberger, R., Aboul-Enein, F., Brueck, W., Lucchinetti, C., Rodriguez, M., Schmidbauer, M., et al. Expression of major histocompatibility complex class I molecules on the different cell types in multiple sclerosis lesions. Brain Pathol 14 (2004), 43–50.
91. Annibali, V., Ristori, G., Angelini, D.F., Serafini, B., Mechelli, R., Cannoni, S., et al. CD161(high)CD8+ T cells bear pathogenetic potential in multiple sclerosis. Brain 134 (2011), 542–554.
92. Ifergan, I., Kebir, H., Alvarez, J.I., Marceau, G., Bernard, M., Bourbonnière, L., et al. Central nervous system recruitment of effector memory CD8+ T lymphocytes during neuroinflammation is dependent on α4 integrin. Brain 134 (2011), 3560–3577.
93. Malmeström, C., Lycke, J., Haghighi, S., Andersen, O., Carlsson, L., Wadenvik, H., et al. Relapses in multiple sclerosis are associated with increased CD8+ T-cell mediated cytotoxicity in CSF. J Neuroimmunol 196 (2008), 159–165.
94. Zang, Y.C.Q., Li, S., Rivera, V.M., Hong, J., Robinson, R.R., Breitbach, W.T., et al. Increased CD8+ cytotoxic T cell responses to myelin basic protein in multiple sclerosis. J Immunol 172 (2004), 5120–5127.
95. Wang, H.H., Dai, Y.Q., Qiu, W., Lu, Z.Q., Peng, F.H., Wang, Y.G., et al. Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J Clin Neurosci 18 (2011), 1313–1317.
96. Billerbeck, E., Kang, Y.-H., Walker, L., Lockstone, H., Grafmueller, S., Fleming, V., et al. Analysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties. Proc Natl Acad Sci U S A 107 (2010), 3006–3011.
97. Illés, Z., Shimamura, M., Newcombe, J., Oka, N., Yamamura, T., Accumulation of Valpha7.2-Jalpha33 invariant T cells in human autoimmune inflammatory lesions in the nervous system. Int Immunol 16 (2004), 223–230.
98. Peterfalvi, A., Gomori, E., Magyarlaki, T., Pal, J., Banati, M., Javorhazy, A., et al. Invariant V 7.2-J 33 TCR is expressed in human kidney and brain tumors indicating infiltration by mucosal-associated invariant T (MAIT) cells. Int Immunol 20 (2008), 1517–1525.
99. Le Bourhis, L., Guerri, L., Dusseaux, M., Martin, E., Soudais, C., Lantz, O., Mucosal-associated invariant T cells: unconventional development and function. Trends Immunol 32 (2011), 212–218.
100. Reantragoon, R., Kjer-Nielsen, L., Patel, O., Chen, Z., Illing, P.T., Bhati, M., et al. Structural insight into MR1-mediated recognition of the mucosal-associated invariant T cell receptor. J Exp Med 209 (2012), 761–774.
101. Kjer-Nielsen, L., Patel, O., Corbett, A.J., Le Nours, J., Meehan, B., Liu, L., et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature 491 (2012), 717–723.
102. Le Bourhis, L., Martin, E., Péguillet, I., Guihot, A., Froux, N., Coré M., et al. Antimicrobial activity of mucosal-associated invariant T cells. Nat Immunol 11 (2010), 701–708.
103. Miyazaki, Y., Miyake, S., Chiba, A., Lantz, O., Yamamura, T., Mucosal-associated invariant T cells regulate Th1 response in multiple sclerosis. Int Immunol 23 (2011), 529–535.
104. Willing, A., Leach, O.A., Ufer, F., Attfield, K.E., Steinbach, K., Kursawe, N., et al. CD8(+) MAIT cells infiltrate into the CNS and alterations in their blood frequencies correlate with IL-18 serum levels in multiple sclerosis. Eur J Immunol 44 (2014), 3119–3128.
105. Lassmann, H., Suchanek, G., Ozawa, K., Histopathology and the blood-cerebrospinal fluid barrier in multiple sclerosis. Ann Neurol 36 (1994), S42–S46.
106. Serafini, B., Rosicarelli, B., Magliozzi, R., Stigliano, E., Aloisi, F., Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 14 (2004), 164–174.
107. Krumbholz, M., Theil, D., Derfuss, T., Rosenwald, A., Schrader, F., Monoranu, C.-M., et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 201 (2005), 195–200.
108. Pitzalis, C., Jones, G.W., Bombardieri, M., Jones, S.A., Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat Rev Immunol 14 (2014), 447–462.
109. Lucchinetti, C.F., Popescu, B.F.G., Bunyan, R.F., Moll, N.M., Roemer, S.F., Lassmann, H., et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 365 (2011), 2188–2197.
110. Obermeier, B., Mentele, R., Malotka, J., Kellermann, J., Kümpfel, T., Wekerle, H., et al. Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat Med 14 (2008), 688–693.
111. Villar, L.M., Sádaba, M.C., Roldán, E., Masjuan, J., González-Porqué P., Villarrubia, N., et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 115 (2005), 187–194.
112. Reindl, M., Di Pauli, F., Rostásy, K., Berger, T., The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 9 (2013), 455–461.
113. Sato, D.K., Callegaro, D., Lana-Peixoto, M.A., Waters, P.J., De Haidar Jorge, F.M., Takahashi, T., et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82 (2014), 474–481.
114. Srivastava, R., Aslam, M., Kalluri, S.R., Schirmer, L., Buck, D., Tackenberg, B., et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med 367 (2012), 115–123.
115. Brickshawana, A., Hinson, S.R., Romero, M.F., Lucchinetti, C.F., Guo, Y., Buttmann, M., et al. Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study. Lancet Neurol 13 (2014), 795–806.
116. Molnarfi, N., Schulze-Topphoff, U., Weber, M.S., Patarroyo, J.C., Prod'homme, T., Varrin-Doyer, M., et al. MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med 210 (2013), 2921–2937.
117. Barr, T.A., Shen, P., Brown, S., Lampropoulou, V., Roch, T., Lawrie, S., et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 209 (2012), 1001–1010.
118. Kieseier, B.C., Stüve, O., A critical appraisal of treatment decisions in multiple sclerosis: old versus new. Nat Rev Neurol 7 (2011), 255–262.
119. Bartholomäus, I., Kawakami, N., Odoardi, F., Schläger, C., Miljkovic, D., Ellwart, J.W., et al. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature 462 (2009), 94–98.
120. Stüve, O., Marra, C.M., Jerome, K.R., Cook, L., Cravens, P.D., Cepok, S., et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 59 (2006), 743–747.
121. Koralnik, I.J., Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name?. Ann Neurol 60 (2006), 162–173.
122. Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 9 (2010), 883–897.